KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.